How existing allergies affect severe respiratory virus infections
Pre-Existing Atopy and Respiratory Viral Infections
['FUNDING_R01'] · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · NIH-11305217
This work looks at whether having allergies before catching a respiratory virus helps protect children and older adults from severe illness.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RESEARCH INST NATIONWIDE CHILDREN'S HOSP (nih funded) |
| Locations | 1 site (COLUMBUS, UNITED STATES) |
| Trial ID | NIH-11305217 on ClinicalTrials.gov |
What this research studies
Researchers are using mouse allergy models (house dust mite) and lab-grown airway cells to learn how pre-existing allergies change the body’s response to respiratory viruses related to RSV. They focus on immune cells called CD11c+ cells that make a protein called neuregulin-1 (NRG1), and on allergy-related signals IL-33 and TSLP that trigger NRG1 production. The team measures viral replication in airway cells in the lab and survival in mice given otherwise-lethal virus doses, and tests whether giving NRG1 can reduce viral damage. Findings will guide whether boosting NRG1 or related pathways could protect the airway lining during infection.
Who could benefit from this research
Good fit: This line of research is most relevant to young children (under 5) and older adults (65+) who are at risk for severe RSV or related respiratory virus infection and who may have or lack allergic conditions.
Not a fit: People with conditions unrelated to respiratory viruses or airway inflammation are unlikely to receive direct benefit from these findings in the near term.
Why it matters
Potential benefit: If successful, the work could point to new ways to protect the airway lining and reduce hospitalizations and deaths from RSV and similar respiratory viruses.
How similar studies have performed: Observational human data and prior mouse studies suggest pre-existing allergy may protect against influenza and SARS-CoV-2, and preliminary mouse experiments here show NRG1 can reduce viral damage, but translating NRG1 into human treatments is still novel.
Where this research is happening
COLUMBUS, UNITED STATES
- RESEARCH INST NATIONWIDE CHILDREN'S HOSP — COLUMBUS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GRAYSON, MITCHELL H — RESEARCH INST NATIONWIDE CHILDREN'S HOSP
- Study coordinator: GRAYSON, MITCHELL H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.